• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To uniQure (QURE) FDA Priority Review

    Simply Wall St·11/14/2026 12:17:55
    Listen to the news
    • uniQure reported third quarter 2026 revenue of US$5.2 million and a net loss of US$61.22 million, alongside FDA acceptance and Priority Review of its Biologics License Application for ifezuntirgene inilparvovec in Huntington’s disease.
    • The FDA’s Priority Review and alignment on a 200 patient confirmatory trial highlight how uniQure’s clinical execution and regulatory planning intersect with a cash intensive operating profile.
    • Investors will now see how uniQure's investment narrative could be reshaped by FDA Priority Review of its Huntington’s gene therapy.
    Seize this moment around uniQure's Huntington’s therapy momentum to compare it with a curated 36 healthcare AI stocks that are also working on high-impact treatments at the edge of medicine and technology.

    uniQure Investment Narrative Recap

    To own uniQure, you need to believe that its Huntington’s disease program can move from an FDA Priority Review into a commercial product while the rest of the gene therapy pipeline matures behind it. The latest quarter shows a small revenue base of US$5.2 million and a sizeable net loss of US$61.22 million, so this is still a funding heavy story.

    The near term upside hinges on the May 1, 2027 PDUFA decision and the related advisory committee. TripleS, an investor in the Simply Wall St Community, frames this as the pivotal moment for the stock. The biggest immediate risk is that a disappointing FDA panel or new data request pushes the key Huntington’s decision and related cash flow expectations much further out.

    The FDA acceptance of the Biologics License Application for ifezuntirgene inilparvovec looks like the announcement that matters most right now. It aligns the short term catalyst around Priority Review, an anticipated advisory committee and uniQure’s ability to get the 200 patient confirmatory trial screening by the end of 2026 as outlined with regulators.

    TripleS argues that this advisory committee is effectively a jury style event that could either keep the accelerated approval path open or redirect the story toward waiting on long term confirmatory outcomes. For you as an investor, that makes execution on the Huntington’s program and trial enrollment logistics far more important than the recent conference appearances or short term share price swings.

    TripleS anchors a fair value of US$60.00 on a scenario where uniQure delivers revenue growth of 149.4% a year and eventually earns a future profit margin of 18.3%. Together, these factors frame a Huntington’s driven commercial model that could support a higher long term earnings power than today’s income statement shows.

    Uncover why uniQure's fair value points to a 152% potential upside to its current price, which could narrow quickly.

    NasdaqGS:QURE 1-Year Stock Price Chart
    NasdaqGS:QURE 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bullish twist in that alternate view is how far some analysts were willing to run with uniQure’s revenue potential. Before this FDA Priority Review news, the most optimistic models were calling for US$1.0b of revenue and earnings of US$293.0 million by about 2029. That is a very different story to today’s losses. Use those gaps as a prompt to compare several narratives, then decide which assumptions you actually trust.

    Explore 5 other uniQure fair value estimates, including one that suggests as much as 1379% upside from the current price.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more uniQure sized ideas?

    If the uniQure story has you thinking about position sizing, risk and potential upside across the rest of your portfolio, it can help to line it up against a broader watchlist built from clear filters in the Simply Wall St Screener.